Literature DB >> 24076099

Levodopa induces long-lasting modification in the functional activity of the nigrostriatal pathway.

Mario Riverol1, Cristina Ordóñez2, María Collantes3, Carla DiCaudo2, Iván Peñuelas3, Javier Arbizu4, Irene Marcilla2, María R Luquin5.   

Abstract

Much controversy exists concerning the effect of levodopa on striatal dopaminergic markers in Parkinson's disease (PD) and its influence on functional neuroimaging. To deal with this issue we studied the impact of neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and chronic levodopa administration on striatal (18)F-DOPA uptake (Ki) in an animal model of PD. The levels of several striatal dopaminergic markers and the number of surviving dopaminergic neurons in the substantia nigra (SN) were also assessed. Eleven Macaca fascicularis were included in the study. Eight animals received weekly intravenous injections of MPTP for 7weeks and 3 intact animals served as controls. MPTP-monkeys were divided in two groups. Group I was treated with placebo while Group II received levodopa. Both treatments were maintained for 11months and then followed by a washout period of 6months. (18)F-DOPA positron emission tomography (PET) scans were performed at baseline, after MPTP intoxication, following 11months of treatment, and after a washout period of 1, 3 and 6months. Monkeys were sacrificed 6months after concluding either placebo or levodopa treatment and immediately after the last (18)F-DOPA PET study. Striatal dopamine transporter (DAT) content, tyrosine hydroxylase (TH) content and aromatic l-amino acid decarboxylase (AADC) content were assessed. In Group II (18)F-DOPA PET studies performed at 3 and 6months after interrupting levodopa showed a significantly increased Ki in the anterior putamen as compared to Group I. Levodopa and placebo treated animals exhibited a similar number of surviving dopaminergic cells in the SN. Striatal DAT content was equally reduced in both groups of animals. Animals in Group I exhibited a significant decrease in TH protein content in all the striatal regions assessed. However, in Group II, TH levels were significantly reduced only in the anterior and posterior putamen. Surprisingly, in the levodopa-treated animals the TH levels in the posterior putamen were significantly lower than those in the placebo group. AADC levels in MPTP groups were similar to those of control animals in all striatal areas analyzed. This study shows that chronic levodopa administration to monkeys with partial nigrostriatal degeneration followed by a washout period induces modifications in the functional activity of the dopaminergic nigrostriatal pathway.
© 2013.

Entities:  

Keywords:  (18)F-DOPA positron emission tomography; Dopaminergic marker; Levodopa; MPTP; Parkinson's disease

Mesh:

Substances:

Year:  2013        PMID: 24076099     DOI: 10.1016/j.nbd.2013.09.014

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  3 in total

1.  The combination of lithium and l-Dopa/Carbidopa reduces MPTP-induced abnormal involuntary movements (AIMs) via calpain-1 inhibition in a mouse model: Relevance for Parkinson׳s disease therapy.

Authors:  Carol A Lazzara; Rebeccah R Riley; Anand Rane; Julie K Andersen; Yong-Hwan Kim
Journal:  Brain Res       Date:  2015-06-26       Impact factor: 3.252

2.  Dissociable Effects of Dopamine on the Initial Capture and the Reactive Inhibition of Impulsive Actions in Parkinson's Disease.

Authors:  Nelleke C van Wouwe; Kristen E Kanoff; Daniel O Claassen; Charis A Spears; Joseph Neimat; Wery P M van den Wildenberg; Scott A Wylie
Journal:  J Cogn Neurosci       Date:  2016-02-02       Impact factor: 3.225

3.  Infinium monkeys: Infinium 450K array for the Cynomolgus macaque (Macaca fascicularis).

Authors:  Mei-Lyn Ong; Peck Yean Tan; Julia L MacIsaac; Sarah M Mah; Jan Paul Buschdorf; Clara Y Cheong; Walter Stunkel; Louiza Chan; Peter D Gluckman; Keefe Chng; Michael S Kobor; Michael J Meaney; Joanna D Holbrook
Journal:  G3 (Bethesda)       Date:  2014-05-08       Impact factor: 3.154

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.